Key result
J-Valve transcatheter treatment addresses native AR affecting up to ~52% of LVAD patients.
Why the study?
Aortic regurgitation can affect 15% to 52% of patients after 1 year of LVAD support and is often progressive.
Key points are not available for this paper at this time.
May offer transcatheter option for post-LVAD AR; leaves open need for prospective trials before practice change.
The use of left ventricular assist devices (LVAD) has expanded rapidly for both destination therapy and as a bridge to transplant.1 Aortic regurgitation (AR) can affect 15% to 52% of these patients after 1 year of LVAD support2,3 and is often progressive.
No takes yet. Share an insight, caveat, or question.
García et al. (2023) studied this question. J-Valve transcatheter treatment addresses native aortic regurgitation, a progressive condition affecting 15% to 52% of patients after 1 year of left ventricular assist device support.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: